Safety of extended treatment with anakinra in patients with rheumatoid arthritis

OBJECTIVE: To determine the safety profile of anakinra after extended exposure in a diverse clinical trial population of patients with rheumatoid arthritis. METHODS: A six month, randomised, double blind phase comparing anakinra (100 mg/day) with placebo was followed by open label anakinra treatment...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Fleischmann, R M, Tesser, J, Schiff, M H, Schechtman, J, Burmester, G‐R, Bennett, R, Modafferi, D, Zhou, L, Bell, D, Appleton, B
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMJ Group 2006
Konular:
Extended Report
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC1798263/
https://ncbi.nlm.nih.gov/pubmed/16396977
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ard.2005.048371
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller